Latham & Watkins represented SoftBank Vision Fund 2 in the transaction. Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Affer in the transaction. Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has announced that it has entered into a definitive agreement...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Vesper Medical in the transaction. Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, has signed an agreement to...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wachtell, Lipton, Rosen & Katz represented Ginkgo Bioworks, while White & Case LLP advised Soaring Eagle Acquisition Corp. in the transaction....
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Senda Biosciences in the transaction. Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field...
You must be a Standard 1 Year member to access this content.
